Cerenome, Inc. (CNSY)
Nasdaq · Healthcare · Biotechnology
$1.56−2.50%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $11.8M
- 52-week range
- $1.49 – $21.50
- 52-week change
- −92.20%
- EPS (trailing)
- −$3.36
- Analyst rating
- 1.3 Strong buy
Fiscal year to Dec 2025
- Revenue
- $5.2M (−10.49%)
- Net income
- −$22.4M
- Operating margin
- −293.5%
- Diluted EPS
- −$0.29
- Free cash flow
- −$20.8M
From the company’s annual report on SEC EDGAR.
About Cerenome, Inc.
Cerenome, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers, by intra-arterial injection. In addition, it develops and commercializes laboratory-developed tests comprising the CNSide Test to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas, as well as develops a data analytics and artificial intelligence platform to integrate diverse data sets into actionable insights that support precision oncology, therapeutic development, and clinical decision-making. The company was formerly known as Plus Therapeutics, Inc. and changed its name to Cerenome, Inc. in August 2026. Cerenome, Inc.
Headquarters: Houston, United States · 28 employees · cerenome.com